Nasal Vaccine Opportunity Abera focuses on mucosal vaccines with proprietary OMV platforms and nasal administration, presenting a clear entry point for partnerships or pilot programs around nasal influenza vaccines and broader respiratory targets.

Influenza Collaboration Recent and ongoing efforts in developing next-generation nasal influenza vaccines create potential collaboration avenues with partners seeking innovative influenza solutions, CEPI-supported in vivo studies, and possibilities with Orexo for powder vaccine formulations.

Powder Vaccine Potential AmorphOX nasal powder vaccine initiatives open conversations with manufacturers and distributors interested in stable, easy-to-handle vaccines for global supply chains, especially in regions with cold chain limitations.

Speed to Market ABer a claims rapid OMV-based manufacturing (14-30 days) suggesting a strong value proposition for customers needing fast timelines, scalable production, and cost efficiencies for multivalent, multi-stage vaccines.

Strategic Partnerships Multiple high-profile collaborations (Orexo, CEPI) indicate a favorable governance and funding environment; leverage these signals to position Abera as a hub for co-development, licensing, or joint ventures in mucosal vaccine platforms.